The Swiss Stock Exchange finished on a negative note on Monday, at the start of a week which will be marked by the publication of the results of several dozen companies, including big arms of the side like Nestlé and Roche on Thursday. Also on Thursday, the European Central Bank will take stock of its monetary policy.
“The ECB should maintain its unchanged rates, with a possible increase in September, but unlikely,” said David Zahn, American active manager Franklin Templeton, in a comment. The markets will listen to the tone of the words of President Christine Lagarde about the commercial risks and the strength of the Euro. “The signals of monetary policy, and not the actions, will guide the reaction of the market,” he said.
In New York, Wall Street was gaining ground in the morning. Investors are also awaiting many business results this week: 135 of the 500 companies that make up the US stock index S&P 500 will publish their financial performance by Friday.
The SMI fell 0.38% to 11,936.89 points, lower at 11,905.44 and higher at 11,993.08. The SLI sold 0.14% to 1986.05 points and the SPI abandoned 0.27% to 16,701.99 points. Of the 31 star values, twelve have lost ground, Swatch Group finished unchanged and the rest fell.
Swiss Re (+1.7%) precedes Julius Bär (+1.5%) and the right schindler (+1.4%) on the podium of the day.
The fortune manager will publish its half -yearly results on Tuesday and analysts interviewed by AWP expect an acceleration of assets under management and new money influx.
The Givaudan perfumes and aromas (+1.2%) also presents its half -yearly results and analysts expect a turnover of 3.9 billion francs for a net profit of 606 million.
The chocolate maker Lindt & Sprüngli (-0.4%) also presents its half-year figures on Tuesday. Turnover is expected at 2.3 billion francs and the net profit at 198 million.
Sonova, Amrize and Adecco (each -1.5%) share the red lantern.
The heavy goods vehicles (-1.2%), Nestlé (-0.9%) and Novartis (-0.8%) weighed on the index.
Roche has undergone a failure as part of a phase III clinical study comparing Astegolimab treatment to a placebo, in addition to standard maintenance treatment in people with chronic obstructive bronchopneumopathy (COPD) moderate to very severe. The main evaluation criterion has not been reached.
Vontobel lowered the objective of courses in the Roche and confirmed “Buy” and Barclays coupon has reduced the course of the Nestlé action course and confirmed “Equal Weight”.
On the enlarged market, Belimo (+1.1%) experienced strong growth in the first half, in particular thanks to its air conditioning solutions for data centers. The Zurich company expects this market to continue to develop.
